Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein

作者：Wang, Yu; Ding, Xiwei; Wang, Shaoqing; Moser, Catherine D.; Shaleh, Hassan M.; Mohamed, Essa A.; Chaiteerakij, Roongruedee; Allotey, Loretta K.; Chen, Gang; Miyabe, Katsuyuki; McNulty, Melissa S.; Ndzengue, Albert; Fritcher, Emily G. Barr; Knudson, Ryan A.; Greipp, Patricia T.; Clark, Karl J.; Torbenson, Michael S.; Kipp, Benjamin R.; Zhou, Jie; Barrett, Michael T.; Gustafson, Michael P.; Alberts, Steven R.; Borad, Mitesh J.; Roberts, Lewis R.^*

来源：Cancer Letters, 2016, 380(1): 163-173.

DOI：10.1016/j.canlet.2016.05.017

• Intrahepatic cholangiocarcinoma
• FGFR2 fusion
• Ponatinib
• Dovitinib
• BGJ398

Cholangiocarcinoma is a highly lethal cancer with limited therapeutic options. Recent genomic analysis of cholangiocarcinoma has revealed the presence of fibroblast growth factor receptor 2 (FGFR2) fusion proteins in up to 13% of intrahepatic cholangiocarcinoma (iCCA). FGFR fusions have been identified as a novel oncogenic and druggable target in a number of cancers. In this study, we established a novel cholangiocarcinoma patient derived xenograft (PDX) mouse model bearing an FGFR2-CCDC6 fusion protein from a metastatic lung nodule of an iCCA patient. Using this PDX model, we confirmed the ability of the FGFR inhibitors, ponatinib, dovitinib and BGJ398, to modulate FGFR signaling, inhibit cell proliferation and induce cell apoptosis in cholangiocarcinoma tumors harboring FGFR2 fusions. In addition, BGJ398 appeared to be superior in potency to ponatinib and dovitinib in this model. Our findings provide a strong rationale for the investigation of FGFR inhibitors, particularly BGJ398, as a therapeutic option for cholangiocarcinoma patients harboring FGFR2 fusions.

• 出版日期2016-9-28
• 单位南京大学; 齐齐哈尔医学院; 南方医科大学